These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36713761)

  • 21. Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis.
    Chugh Y; Gupta K; Krishna HB; Ayala RQ; Zepeda I; Grushko M; Faillace RT
    Pacing Clin Electrophysiol; 2023 Jan; 46(1):50-58. PubMed ID: 36419246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.
    Murakawa Y; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Heart Vessels; 2020 Aug; 35(8):1125-1134. PubMed ID: 32253531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
    Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S; Eikelboom JW
    J Am Coll Cardiol; 2021 Feb; 77(5):511-525. PubMed ID: 33538248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation.
    Lee SR; Choi EK; Jung JH; Park SH; Han KD; Oh S; Lip GYH
    Stroke; 2021 Jan; 52(2):521-530. PubMed ID: 33423512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation.
    Lee SR; Rhee TM; Kang DY; Choi EK; Oh S; Lip GYH
    Am J Cardiol; 2019 Sep; 124(6):879-885. PubMed ID: 31311662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories.
    Kaplan RM; Tanaka Y; Passman RS; Fine M; Rasmussen-Torvik LJ; Vupputuri S; Martin K; Khan SS
    J Am Heart Assoc; 2020 Dec; 9(24):e017383. PubMed ID: 33302751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation.
    Choi Y; Lee Y; Kim SH; Kim S; Kim JY; Kim TS; Hwang Y; Kim JH; Jang SW; Lee MY; Oh YS
    Heart; 2022 Feb; 108(4):285-291. PubMed ID: 33990409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
    Lucijanic M; Jurin I; Jurin H; Lucijanic T; Starcevic B; Skelin M; Glasnovic A; Catic J; Jurisic A; Hadzibegovic I
    Int J Cardiol; 2020 Feb; 301():90-95. PubMed ID: 31748190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".
    Fischer Q; Georges JL; Le Feuvre C; Sharma A; Hammoudi N; Berman E; Cohen S; Jolivet I; Silvain J; Helft G
    Int J Cardiol; 2018 Aug; 264():64-69. PubMed ID: 29776575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
    Kawakami S; Yasuda S; Ogawa H
    J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
    Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
    Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
    Sandhu RK; Ezekowitz J; Andersson U; Alexander JH; Granger CB; Halvorsen S; Hanna M; Hijazi Z; Jansky P; Lopes RD; Wallentin L
    Eur Heart J; 2016 Oct; 37(38):2869-2878. PubMed ID: 27071819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.
    Matsumura-Nakano Y; Shizuta S; Komasa A; Morimoto T; Masuda H; Shiomi H; Goto K; Nakai K; Ogawa H; Kobori A; Kono Y; Kaitani K; Suwa S; Aoyama T; Takahashi M; Sasaki Y; Onishi Y; Mano T; Matsuda M; Motooka M; Tomita H; Inoko M; Wakeyama T; Hagiwara N; Tanabe K; Akao M; Miyauchi K; Yajima J; Hanaoka K; Morino Y; Ando K; Furukawa Y; Nakagawa Y; Nakao K; Kozuma K; Kadota K; Kimura K; Kawai K; Ueno T; Okumura K; Kimura T;
    Circulation; 2019 Jan; 139(5):604-616. PubMed ID: 30586700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis.
    Ullah W; Sattar Y; Shaukat M; Fischman DL
    Eur J Intern Med; 2020 Nov; 81():54-59. PubMed ID: 32709546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m
    O'Kane CP; Avalon JCO; Lacoste JL; Fang W; Bianco CM; Davisson L; Piechowski KL
    Pharmacotherapy; 2022 Feb; 42(2):112-118. PubMed ID: 34820876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.